Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016 (2016), Article ID 2481865, 17 pages
http://dx.doi.org/10.1155/2016/2481865
Research Article

Histone Deacetylase Inhibitors Increase p27Kip1 by Affecting Its Ubiquitin-Dependent Degradation through Skp2 Downregulation

1Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, 80138 Naples, Italy
2Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università degli Studi di Firenze, 50134 Firenze, Italy
3Dipartimento di Scienze Cardiotoraciche e Respiratorie, Seconda Università di Napoli, 80131 Napoli, Italy

Received 18 December 2014; Revised 2 August 2015; Accepted 9 August 2015

Academic Editor: Peter Backx

Copyright © 2016 Adriana Borriello et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. L. Berger, “The complex language of chromatin regulation during transcription,” Nature, vol. 447, no. 7143, pp. 407–412, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Kouzarides, “Chromatin modifications and their function,” Cell, vol. 128, no. 4, pp. 693–705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. M. A. Dawson and T. Kouzarides, “Cancer epigenetics: from mechanism to therapy,” Cell, vol. 150, no. 1, pp. 12–27, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. K. J. Falkenberg and R. W. Johnstone, “Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders,” Nature Reviews Drug Discovery, vol. 13, no. 9, pp. 673–691, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. H. A. Tissenbaum and L. Guarente, “Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans,” Nature, vol. 410, no. 6825, pp. 227–230, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Dawson, T. Kouzarides, and B. J. P. Huntly, “Targeting epigenetic readers in cancer,” The New England Journal of Medicine, vol. 367, no. 7, pp. 647–657, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. C. West and R. W. Johnstone, “New and emerging HDAC inhibitors for cancer treatment,” The Journal of Clinical Investigation, vol. 124, no. 1, pp. 30–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Staiano-Coico, M. Steinberg, and P. J. Higgins, “Epidermal cell-shape regulation and subpopulation kinetics during butyrate-induced terminal maturation of normal and SV40-transformed human keratinocytes: epithelial models of differentiation therapy,” International Journal of Cancer, vol. 46, no. 4, pp. 733–738, 1990. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Hague, A. M. Manning, K. A. Hanlon, L. I. Huschtscha, D. Hart, and C. Paraskeva, “Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer,” International Journal of Cancer, vol. 55, no. 3, pp. 498–505, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. B. G. Heerdt, M. A. Houston, and L. H. Augenlicht, “Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines,” Cancer Research, vol. 54, no. 12, pp. 3288–3293, 1994. View at Google Scholar · View at Scopus
  11. E. C. Aguilar, A. J. Leonel, L. G. Teixeira et al., “Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFκB activation,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 24, no. 6, pp. 606–613, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. S. P. Perrine, M. F. Greene, and D. V. Faller, “Delay in the fetal globin switch in infants of diabetic mothers,” The New England Journal of Medicine, vol. 312, no. 6, pp. 334–338, 1985. View at Publisher · View at Google Scholar · View at Scopus
  13. S. P. Perrine, A. Rudolph, D. V. Faller et al., “Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 22, pp. 8540–8542, 1988. View at Publisher · View at Google Scholar · View at Scopus
  14. S. P. Perrine, G. D. Ginder, D. V. Faller et al., “A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders,” The New England Journal of Medicine, vol. 328, no. 2, pp. 81–86, 1993. View at Publisher · View at Google Scholar · View at Scopus
  15. D. V. Faller and S. P. Perrine, “Butyrate in the treatment of sickle cell disease and β-thalassemia,” Current Opinion in Hematology, vol. 2, no. 2, pp. 109–117, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. S. P. Perrine, O. Hermine, T. Small et al., “A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies,” Blood, vol. 109, no. 6, pp. 2571–2578, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. V. M. Richon, Y. Webb, R. Merger et al., “Second generation hybrid polar compounds are potent inducers of transformed cell differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 12, pp. 5705–5708, 1996. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Göttlicher, S. Minucci, P. Zhu et al., “Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells,” The EMBO Journal, vol. 20, no. 24, pp. 6969–6978, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Besson, S. F. Dowdy, and J. M. Roberts, “CDK inhibitors: cell cycle regulators and beyond,” Developmental Cell, vol. 14, no. 2, pp. 159–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Borriello, V. Cucciolla, A. Oliva, V. Zappia, and F. Della Ragione, “p27Kip1 metabolism: a fascinating labyrinth,” Cell Cycle, vol. 6, no. 9, pp. 1053–1061, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Borriello, D. Bencivenga, M. Criscuolo et al., “Targeting p27Kip1 protein: its relevance in the therapy of human cancer,” Expert Opinion on Therapeutic Targets, vol. 15, no. 6, pp. 677–693, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Della Ragione, V. Cucciolla, V. Criniti, S. Indaco, A. Borriello, and V. Zappia, “p21cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect,” Journal of Biological Chemistry, vol. 278, no. 26, pp. 23360–23368, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Borriello, V. Della Pietra, M. Criscuolo et al., “p27Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation,” Oncogene, vol. 19, no. 1, pp. 51–60, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Cucciolla, A. Borriello, M. Criscuolo et al., “Histone deacetylase inhibitors upregulate p57Kip2 level by enhancing its expression through Sp1 transcription factor,” Carcinogenesis, vol. 29, no. 3, pp. 560–567, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Bencivenga, A. Tramontano, A. Borgia et al., “p27Kip1 serine 10 phosphorylation determines its metabolism and interaction with cyclin-dependent kinases,” Cell Cycle, vol. 13, no. 23, pp. 3768–3782, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Borriello, V. Cucciolla, M. Criscuolo et al., “Retinoic acid induces p27 Kip1 nuclear accumulation by modulating its phosphorylation,” Cancer Research, vol. 66, no. 8, pp. 4240–4248, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Ocker and R. Schneider-Stock, “Histone deacetylase inhibitors: signalling towards p21cip1/waf1,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 7-8, pp. 1367–1374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Borriello, I. Caldarelli, D. Bencivenga et al., “p57Kip2 and cancer: time for a critical appraisal,” Molecular Cancer Research, vol. 9, no. 10, pp. 1269–1284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. Q. Wang, Y. Zhou, X. Wang, and B. M. Evers, “p27Kip1 nuclear localization and cyclin-dependent kinase inhibitory activity are regulated by glycogen synthase kinase-3 in human colon cancer cells,” Cell Death and Differentiation, vol. 15, no. 5, pp. 908–919, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Uehara, K. Yoshizawa, and A. Tsubura, “Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells,” Oncology Reports, vol. 28, no. 1, pp. 105–110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. W. Jiang, Q. Guo, J. Wu et al., “Dual effects of sodium butyrate on hepatocellular carcinoma cells,” Molecular Biology Reports, vol. 39, no. 5, pp. 6235–6242, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. E. S. Yang and K. L. Burnstein, “Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm,” The Journal of Biological Chemistry, vol. 278, no. 47, pp. 46862–46868, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Bashir, N. V. Dorrello, V. Amado, D. Guardavaccaro, and M. Pagano, “Control of the SCFSkp2-Cks1 ubiquitin ligase by the APC/CCdh1 ubiquitin ligase,” Nature, vol. 428, no. 6979, pp. 190–193, 2004. View at Publisher · View at Google Scholar
  34. W. Wei, N. G. Ayad, Y. Wan, G.-J. Zhang, M. W. Kirschner, and W. G. Kaelin Jr., “Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex,” Nature, vol. 428, no. 6979, pp. 194–198, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. H.-K. Lin, G. Wang, Z. Chen et al., “Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB,” Nature Cell Biology, vol. 11, no. 4, pp. 420–432, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Gao, H. Inuzuka, A. Tseng, R. Y. Chin, A. Toker, and W. Wei, “Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction,” Nature Cell Biology, vol. 11, no. 4, pp. 397–408, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Rodier, P. Coulombe, P.-L. Tanguay, C. Boutonnet, and S. Meloche, “Phosphorylation of Skp2 regulated by CDK2 and Cdc14B protects it from degradation by APCCdh1 in G1 phase,” The EMBO Journal, vol. 27, no. 4, pp. 679–691, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Cantoni, M. Galletti, F. Zambelli et al., “Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition,” FEBS Journal, vol. 280, no. 9, pp. 2042–2055, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. C.-S. Chen, S.-C. Weng, P.-H. Tseng, H.-P. Lin, and C.-S. Chen, “Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes,” The Journal of Biological Chemistry, vol. 280, no. 46, pp. 38879–38887, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. R. V. Lloyd, L. A. Erickson, L. Jin et al., “p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers,” The American Journal of Pathology, vol. 154, no. 2, pp. 313–323, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. R. L. Piekarz, R. Robey, V. Sandor et al., “Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report,” Blood, vol. 98, no. 9, pp. 2865–2868, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. J. E. Bolden, M. J. Peart, and R. W. Johnstone, “Anticancer activities of histone deacetylase inhibitors,” Nature Reviews Drug Discovery, vol. 5, no. 9, pp. 769–784, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. E. A. Olsen, Y. H. Kim, T. M. Kuzel et al., “Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma,” Journal of Clinical Oncology, vol. 25, no. 21, pp. 3109–3115, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. S. J. Whittaker, M.-F. Demierre, E. J. Kim et al., “Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma,” Journal of Clinical Oncology, vol. 28, no. 29, pp. 4485–4491, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. R. L. Piekarz, R. Frye, M. Turner et al., “Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5410–5417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. N. A. Barlev, L. Liu, N. H. Chehab et al., “Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases,” Molecular Cell, vol. 8, no. 6, pp. 1243–1254, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Faiola, X. Liu, S. Lo et al., “Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription,” Molecular and Cellular Biology, vol. 25, no. 23, pp. 10220–10234, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Matsuzaki, H. Daitoku, M. Hatta, H. Aoyama, K. Yoshimochi, and A. Fukamizu, “Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 32, pp. 11278–11283, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Tsihlias, L. Kapusta, and J. Slingerland, “The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer,” Annual Review of Medicine, vol. 50, pp. 401–423, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Sgambato, A. Cittadini, B. Faraglia, and I. B. Weinstein, “Multiple functions of p27(Kip1) and its alterations in tumor cells: a review,” Journal of Cellular Physiology, vol. 183, no. 1, pp. 18–27, 2000. View at Google Scholar · View at Scopus
  51. M. Pagano, S. W. Tam, A. M. Theodoras et al., “Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27,” Science, vol. 269, no. 5224, pp. 682–685, 1995. View at Publisher · View at Google Scholar · View at Scopus
  52. A. C. Carrano, E. Eytan, A. Hershko, and M. Pagano, “SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27,” Nature Cell Biology, vol. 1, no. 4, pp. 193–199, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Sutterlüty, E. Chatelain, A. Marti et al., “p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells,” Nature Cell Biology, vol. 1, no. 4, pp. 207–214, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Spruck, H. Strohmaier, M. Watson et al., “A CDK-independent function of mammalian Cks1: targeting of SCFSkp2 to the CDK inhibitor p27Kip1,” Molecular Cell, vol. 7, no. 3, pp. 639–650, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Hara, T. Kamura, K. Nakayama, K. Oshikawa, S. Hatakeyama, and K.-I. Nakayama, “Degradation of p27Kip1 at the G0-G1 transition mediated by a Skp2-independent ubiquitination pathway,” The Journal of Biological Chemistry, vol. 276, no. 52, pp. 48937–48943, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. N. P. Malek, H. Sundberg, S. McGrew, K. Nakayama, T. R. Kyriakidis, and J. M. Roberts, “A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase,” Nature, vol. 413, no. 6853, pp. 323–327, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Kamura, T. Hara, M. Matsumoto et al., “Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase,” Nature Cell Biology, vol. 6, no. 12, pp. 1229–1235, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Kotoshibai, T. Kamura, T. Hara, N. Ishida, and K. I. Nakayama, “Molecular dissection of the interaction between p27 and Kip1 ubiquitylation-promoting complex, the ubiquitin ligase that regulates proteolysis of p27 in G1 phase,” The Journal of Biological Chemistry, vol. 280, no. 18, pp. 17694–17700, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Besson, M. Gurian-West, X. Chen, K. S. Kelly-Spratt, C. J. Kemp, and J. M. Roberts, “A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression,” Genes and Development, vol. 20, no. 1, pp. 47–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Imaki, K. Nakayama, S. Delehouzee et al., “Cell cycle-dependent regulation of the Skp2 promoter by GA-binding protein,” Cancer Research, vol. 63, no. 15, pp. 4607–4613, 2003. View at Google Scholar · View at Scopus
  61. H. Inuzuka, D. Gao, L. W. S. Finley et al., “Acetylation-dependent regulation of Skp2 function,” Cell, vol. 150, no. 1, pp. 179–193, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Frescas and M. Pagano, “Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer,” Nature Reviews Cancer, vol. 8, no. 6, pp. 438–449, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. D. D. Hershko, “Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer,” Cancer, vol. 112, no. 7, pp. 1415–1424, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. O. H. Krämer, P. Zhu, H. P. Ostendorff et al., “The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2,” The EMBO Journal, vol. 22, no. 13, pp. 3411–3420, 2003. View at Publisher · View at Google Scholar · View at Scopus